| Literature DB >> 35010512 |
Abdul Haseeb1, Hani Saleh Faidah2, Manal Algethamy3, Saleh Alghamdi4, Ghaidaa Ali Alhazmi5, Afnan Owedah Alshomrani6, Bashair Rjyan Alqethami7, Hind Saeed Alotibi8, Maali Zayed Almutiri9, Khawlah Saad Almuqati10, Amjad Abdullah Albishi11, Mahmoud Essam Elrggal1, Ahmad Jamal Mahrous1, Asim Abdulaziz Khogeer12,13, Zikria Saleem14, Muhammad Shahid Iqbal15, Aziz Sheikh16.
Abstract
(1) Background: Inappropriate use of antimicrobials and subsequently rise of antimicrobial resistance (AMR) remains a major public health priority. Over-prescribing of broad-spectrum antibiotics is one of the main contributing factors for the emergence of AMR. We sought to describe antimicrobial prescribing trends among patients in public hospitals in Makkah hospitals. (2) Method: We undertook a point prevalence survey (PPS) in six hospitals in Makkah, Saudi Arabia, from January 2019 to July 2019. The survey included all the inpatients receiving antimicrobials on the day of PPS. Data was collected using the Global point prevalence survey (PPS) tool developed by the University of Antwerp, Belgium. (3)Entities:
Keywords: Saudi Arabia; antimicrobial consumption; antimicrobial resistance; hospital; point prevalence survey
Mesh:
Substances:
Year: 2021 PMID: 35010512 PMCID: PMC8782433 DOI: 10.3390/ijerph19010254
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Overall antibiotic use prevalence.
| Characteristics N (%) | H1 | H2 | H3 | H4 | H5 | H6 | Total | Range |
|---|---|---|---|---|---|---|---|---|
| Hospital Type | ||||||||
| Total beds | 175 | 180 | 118 | 174 | 283 | 20 | 950 | 20–283 |
| Hospitalized patients | 122 (69.7) | 152 (84.4) | 96 (81.3) | 121 (69.5) | 202 (71.3) | 15 (75.0) | 710 (74.7) | 69.5–84.4 |
| Treated patients | 79 (64.7) | 82 (53.9) | 67 (69.8) | 57 (47.1) | 141 (69.8) | 14 (93.3) | 440 (61.9) | 47.1–93.3 |
| Prescribed antibiotics (per patient) | 140 (1.7) | 150 (1.8) | 129 (1.9) | 106 (1.8) | 229 (1.6) | 19 (1.3) | 773 (1.7) | 1.3–1.9 |
| Departments | ||||||||
| Surgical Department | 32 (22.9) | 25 (16.7) | 33 (25.6) | 12 (11.3) | 81 (35.4) | - | 183 (23.7) | 11.3–35.4 |
| Medical Department | 74 (52.9) | 125 (83.3) | 39 (30.2) | 71 (67.0) | 106 (46.3) | - | 415 (53.7) | 30.2–83.3 |
| Intensive Care Unit | 34 (24.3) | - | 57 (44.2) | 23 (21.7) | 42 (18.3) | 19 (100) | 175 (22.6) | 0–100 |
| Gender | ||||||||
| Male | 74 (52.9) | 42 (28.0) | 70 (54.3) | 70 (66.0) | 143 (62.4) | 10 (52.6) | 409 (52.9) | 28.0–66.0 |
| Female | 66 (47.1) | 105 (70.0) | 54 (41.9) | 36 (34.0) | 86 (37.6) | 9 (47.4) | 356 (46.1) | 34.0–70.0 |
| Route of administration | ||||||||
| Oral | 13 (9.3) | 15 (10.0) | 5 (3.9) | 12 (11.3) | 25 (10.9) | 5 (26.3) | 75 (9.7) | 3.9–26.3 |
| Parenteral | 127 (90.7) | 135 (90.0) | 124 (96.1) | 94 (88.7) | 204 (89.1) | 14 (73.7) | 698 (90.3) | 73.7–96.1 |
| Indication | ||||||||
| Community-acquired infection | 56 (40.0) | 132 (88.0) | 37 (28.7) | 44 (41.5) | 114 (49.8) | 19 (100.0) | 402 (52.0) | 40.0–100.0 |
| Hospital-acquired infection | 73 (52.1) | 18 (12.0) | 27 (20.9) | 40 (37.6) | 60 (26.2) | - | 218 (28.1) | 0.0–52.1 |
| Medical prophylaxis | - | - | - | 2 (1.9) | 5 (2.2) | - | 7 (0.9) | 0.0–2.2 |
| Surgical prophylaxis (single dose) | 3 (2.1) | - | 4 (3.1) | 5 (4.7) | 7 (3.1) | - | 19 (2.5) | 0.0–4.7 |
| Surgical prophylaxis (one day) | 4 (2.9) | - | 13 (10.1) | 4 (3.8) | 11 (4.8) | - | 32 (4.1) | 0.0–10.1 |
| Surgical prophylaxis (>1 day) | 4 (2.9) | - | 1 (0.8) | 9 (8.5) | 26 (11.4) | - | 40 (5.2) | 0.0–11.4 |
| Others | - | - | 47 (36.5) | 2 (1.9) | 6 (2.6) | - | 55 (7.1) | 0.0–36.5 |
| Treatment | ||||||||
| Empirical therapy | 108 (77.1) | 143 (95.3) | 107 (82.9) | 89 (84.0) | 194 (84.7) | 19 (100.0) | 660 (85.4) | 77.1–100.0 |
| Targeted therapy | 32 (22.9) | 7 (4.7) | 22 (17.1) | 17 (16.0) | 35 (15.3) | - | 113 (14.6) | 0.0–22.9 |
| Guideline’s compliance | ||||||||
| Yes | 70 (50.0) | 12 (8.0) | 54 (41.9) | 17 (16.0) | 57 (24.9) | 14 (78.9) | 225 (29.1) | 8.0–78.9 |
| No | 65 (46.4) | - | 1 (0.8) | 10 (9.4) | 31 (13.5) | 4 (21.1) | 111 (14.4) | 0.0–46.4 |
| NA | - | - | 25 (19.4) | 4 (3.8) | 25 (10.9) | - | 54 (7.0) | 0.0–19.4 |
| NI | 5 (3.6) | 138 (92.0) | 49 (38.0) | 75 (70.8) | 116 (50.7) | - | 383 (49.5) | 0.0–92.0 |
| Stop date documented | 35 (25.0) | 57 (38.0) | 29 (22.5) | 49 (46.2) | 74 (32.3) | 16 (84.2) | 260 (33.6) | 22.5–84.2 |
| Reason on notes | 79 (56.4) | 54 (36.0) | 84 (65.1) | 56 (52.8) | 150 (65.5) | 16 (84.2) | 439 (56.8) | 36.0–84.2 |
| Culture Reports | 32 | 7 | 22 | 34 | 37 | 0 | 132 | 0–37 |
Use the prevalence of main antibiotics classes.
| Antibiotics | |
|---|---|
| ANTIBACTERIALS FOR SYSTEMIC USE (J01) | 744 (96.2) |
| Tetracyclines (J01A) | 14 (1.8) |
| Amphenicols (J01B) | 1 (0.1) |
| Penicillins (J01C) | 151 (19.5) |
| Cephalosporins and Penams (J01D) | 285 (36.9) |
| Sulfonamides and trimethoprim (J01E) | 3 (0.4) |
| Macrolides and lincosamides (J01F) | 77 (10.0) |
| Aminoglycosides (J01G) | 23 (3.0) |
| Quinolones (J01M) | 74 (9.6) |
| Other antibacterials (J01X) | 116 (15.0) |
| Antimycotics for systemic use(J02) | 8 (1.0) |
| Antimycobacterials FOR SYSTEMIC USE (J04) | 11 (1.4) |
| Antivirals FOR SYSTEMIC USE (J05) | 8 (1.0) |
| Antiprotozoals (P01) | 2 (0.3) |
Top 10 indications and antibiotics.
| Top 10 Indications | Top 10 Antibiotics | |||
|---|---|---|---|---|
| No. | Indications | Antibiotics | ||
| 1 | Pneumonia | 134 (17.3) | Ceftriaxone | 116 (15.0) |
| 2 | Others | 111 (14.4) | Piperacillin, enzyme inhibitor | 84 (10.9) |
| 3 | SST | 84 (10.9) | Metronidazole | 55 (7.1) |
| 4 | Unknown | 67 (8.7) | Cefuroxime | 45 (5.8) |
| 5 | SEPSIS | 51 (6.6) | Levofloxacin | 45 (5.8) |
| 6 | OBGY | 42 (5.4) | Meropenam | 42 (5.4) |
| 7 | BJ | 38 (4.9) | Clindamycin | 41 (5.3) |
| 8 | CNS | 28 (3.6) | Vancomycin | 37 (4.8) |
| 9 | CVS | 25 (3.2) | Cefazolin | 35 (4.5) |
| 10 | P. GIT | 25 (3.2) | Ciprofloxacin | 25 (3.2) |
BJ; Bone and Joint, CNS; Central Nervous System, GIT; Gastro-Intestinal Tract, OBGY; Obstetric or Gynaecological, P; Prophylaxis, SST; Skin and Soft Tissues.
Figure 1Common pathogens reported in hospitals.